This study is looking into a new drug, BMS-986365, for men with metastatic castration-resistant prostate cancer (prostate cancer that has spread and is no longer responding to hormone therapy). It compares BMS-986365 to standard treatments like enzalutamide, abiraterone, or docetaxel, which may be given with prednisone/prednisolone. The main goal is to see if BMS-986365 can stop the cancer from growing or spreading for longer than current treatments. You might be able to join if you are an adult male with prostate cancer that has spread and has been confirmed by a doctor. The study is currently unclear on its recruitment status and plans to enroll 960 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive either BMS-986365 or one of the standard treatments. In Part 1, participants are assigned to one of two doses of BMS-986365 or a standard treatment, while in Part 2, they are assigned to one selected dose of BMS-986365 or a standard treatment.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 4 years to track how long the cancer is kept from growing or spreading.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.